Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Jose Luis Cuadra"'
Autor:
Giulia Martini, Rodrigo Dienstmann, Javier Ros, Iosune Baraibar, Jose Luis Cuadra-Urteaga, Francesc Salva, Davide Ciardiello, Nuria Mulet, Guillem Argiles, Josep Tabernero, Elena Elez
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Colorectal cancer (CRC) is a heterogeneous disease representing a therapeutic challenge, which is further complicated by the common occurrence of several molecular alterations that confer resistance to standard chemotherapy and targeted agents. Mecha
Externí odkaz:
https://doaj.org/article/6654e5c3559c4202a4a19cbc5b7e1603
Autor:
Jose Luis Cuadra-Urteaga, Nuria Mulet, Javier Ros, Elena Elez, Iosune Baraibar, Nadia Saoudi Gonzalez, Josep Tabernero, A. Valdivia, Francesc Salvà, D. Marmolejo
Publikováno v:
Expert Opinion on Biological Therapy. 21:1315-1324
Introduction: Colorectal cancer (CRC) is a major public health problem. Despite major progress understanding the biological basis of this tumor added to the incorporation of optimized diagnostic an...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf57f170a11d61a10718b277040a89e8
https://doi.org/10.1080/14712598.2021.1935231
https://doi.org/10.1080/14712598.2021.1935231
Autor:
Elena Élez, Núria Mulet-Margalef, Miriam Sanso, Fiorella Ruiz-Pace, Francesco M. Mancuso, Raquel Comas, Javier Ros, Guillem Argilés, Giulia Martini, Enrique Sanz-Garcia, Iosune Baraibar, Francesc Salvà, Alba Noguerido, Jose Luis Cuadra-Urteaga, Roberta Fasani, Ariadna Garcia, Jose Jimenez, Susana Aguilar, Stefania Landolfi, Javier Hernández-Losa, Irene Braña, Paolo Nuciforo, Rodrigo Dienstmann, Josep Tabernero, Ramon Salazar, Ana Vivancos
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 1; Pages: 118
Scientia
Scientia
Biomarkers; Colorectal cancer; Immunotherapy Biomarcadors; Càncer colorectal; Immunoteràpia Biomarcadores; Cáncer colorrectal; Inmunoterapia The search for immunotherapy biomarkers in Microsatellite Instability High/Deficient Mismatch Repair syste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70bacfe4702a115d21d52cef1988afcb
https://doi.org/10.3390/ijms24010118
https://doi.org/10.3390/ijms24010118
Autor:
Guillem Argiles, Giulia Martini, Emilia Sardo, Davide Ciardiello, Josep Tabernero, Nuria Mulet, Javier Ros, Francesc Salvà, Elena Elez, Iosune Baraibar, Jose Luis Cuadra
Publikováno v:
Therapeutic Advances in Medical Oncology
Scientia
Scientia
Inhibidor de BRAF; Binimetinib; Cáncer de colon BRAF inhibitor; Binimetinib; Colon cancer Inhibidor de BRAF; Binimetinib; Càncer de còlon Introduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be0bc2e68ffac8dc6252e900583f556f
http://europepmc.org/articles/PMC7903827
http://europepmc.org/articles/PMC7903827
Autor:
Francesc Salvà, Iosune Baraibar, Nuria Mulet, Josep Tabernero, Rodrigo Dienstmann, Davide Ciardiello, Giulia Martini, Guillem Argiles, Javier Ros, Elena Elez, Jose Luis Cuadra-Urteaga
Publikováno v:
Therapeutic Advances in Medical Oncology
Scientia
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Scientia
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Biomarcadors; Càncer colorectal; Classificació molecular Biomarcadores; Cáncer colorrectal; Clasificación molecular Biomarkers; Colorectal cancer; Molecular classification Colorectal cancer (CRC) is a heterogeneous disease representing a therapeu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60677e7f153a438bc690ddb31072791e
http://europepmc.org/articles/PMC7383645
http://europepmc.org/articles/PMC7383645
Autor:
Davide Ciardiello, Jose Luis Cuadra, Nuria Mulet, Javier Ros, Iosune Baraibar, Guillem Argiles, Josep Tabernero, Francesc Salvà, Elena Elez, Giulia Martini, Emilia Sardo
Introduction: Molecular profiling has led to significantly longer survival in metastatic colorectal cancer (mCRC) patients. Clinical guidelines recommend testing for KRAS/NRAS, BRAF and MSI status, and new biomarkers such as HER2 amplification and NT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d59f64a9462acc4e7d583e58571b0a1
http://hdl.handle.net/11591/462659
http://hdl.handle.net/11591/462659
Autor:
Helena Verdaguer, Nuria Mulet, Francesc Salvà, J. Hernando, Raquel Comas, Elena Elez, A. Valdivia, Jose Luis Cuadra, Eloy Espin, Stefania Landolfi, Mireia Sanchis, Ariadna Garcia, Jaume Capdevila, Javier Ros, Josep Tabernero, Marc Martí, Ana Virgili, Paolo Nuciforo, Nadia Saoudi, Iosune Baraibar
Publikováno v:
Web of Science
10563 Background: Young-onset colorectal cancer (YOCR) is defined as diagnosis below the age of 50. Over the past decades, the incidence of YOCRC has increased at an alarming rate, but causes and pathogenesis still remain unknown. Early detection of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13dc02245a6f02f81e6b9f2ea46776cc
https://doi.org/10.1200/jco.2021.39.15_suppl.10563
https://doi.org/10.1200/jco.2021.39.15_suppl.10563
Publikováno v:
Cancer Biology & Therapy. 17:233-236
Carcinosarcomas (CS) are biphasic tumors with malignant epithelial and mesenchymal elements. The sarcomatoid elements of CS can include chondrosarcoma, malignant fibrous histiocytoma, osteosarcoma, leiomyosarcoma, fibrosarcoma, or liposarcoma. CS of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24c66e9ebefcbd279d4d672e7ac6d23d
https://doi.org/10.1080/15384047.2016.1139237
https://doi.org/10.1080/15384047.2016.1139237
Autor:
Elena Elez, Raquel Comas, Josep Tabernero, Bernardo Queralt, Javier Ros Montañá, Davide Ciardiello, Rodrigo Dienstmann, Ana Vivancos, Rodrigo A. Toledo, Guillem Argiles, Xavier Hernandez Yague, Antonieta Salud Salvia, Nuria Mulet, Jose Luis Cuadra, Hector G. Palmer, Ariadna Garcia, Iosune Baraibar, Giulia Martini, Guillermo Villacampa, Irene Chicote
Publikováno v:
Web of Science
4112 Background: BRAF V600 mt mCRC is an aggressive disease with poor OS under standard chemotherapy. Treatment with doublet and triplet targeted combinations, such as BRAF inhibitor+ antiEGFR+/- MEK inhibitor, has been shown to improve outcomes. Pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::460c4929c7a604858bbd7c7617691d71
https://doi.org/10.1200/jco.2020.38.15_suppl.4112
https://doi.org/10.1200/jco.2020.38.15_suppl.4112
Autor:
Noelia Pérez, Elena Elez, María Teresa Fernández-Figueras, Nina A. Richarz, Jose Luis Cuadra-Urteaga, Luis Puig
Publikováno v:
CANCER BIOLOGY & THERAPY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Neutrophilic panniculitis is an infrequent but characteristic adverse event under therapy with BRAF inhibitors (BRAFi). Since the approval of vemurafenib for treatment of metastatic melanoma in 2011, only two cases of neutrophilic panniculitis in mal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66cf1cbbfd137e87c0f65b4499991ee6
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3936
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3936